For years, the development of drugs for respiratory diseases, mainly asthma and chronic obstructive pulmonary disease (COPD), have relied on the administration of a new drug, mostly by inhalation and assessment by physiologic tests and questionnaires. More and more these new drugs are administered in fixed combinations.
This white paper outlines the latest respiratory R&D trends encompassing outcomes and clinical trial study designs.
O'FIVE Plaza, Plot 1046, Haile Selassie Road,
P.O Box 2249, Msasani Peninsula,
Dar Es Salaam, Tanzania